Goldman Sachs has upgraded BioNTech SE BNTX, citing the company’s BNT327, an immuno-oncology asset in clinical development across multiple solid tumors.Data from Summit Therapeutics Inc. SMMT and their partner Akeso for ivonescimab (PD-1xVEGF bispecific) has shown the potential to challenge standard-of-care regimens across a range of solid tumors.The analyst notes that the data for ivonescimab have sparked interest in BioNTech’s bispecific drug, BNT327, and its potential to follow a similar path and gain va ...